10:01 AM EST - Valeant Pharmaceuticals International, Inc. : Said its Ortho Dermatologics division announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading down $0.67 at $14.67.
